This study aims to assess the safety tolerability, adherence and effectiveness of genistein as an anti-obesity treatment for children and adolescents. The primary goal is determining how well genistein is tolerated and adhered to by pediatric patients with obesity. Secondary goals include evaluating its impact on body mass index z-scores and cardiometabolic risk factors, such as inflammation.
Participants aged 4-18 will be recruited from the Paediatric HEAL (Healthy Eating, Activity & Lifestyle) Program at the Children's Hospital - London Health Science Center in London, Ontario. They will receive genistein treatment over 6 months, with interim assessments at 3 and 6 months to monitor efficacy, safetytolerability, and adherence, and efficacy, and potentially increase the dose at the 3-month visit. A final assessment will occur after a 3-month washout to observe any lasting effects.
Blood and urine samples will be collected to analyze various adherence and health markers, including inflammatory and cardiometabolic factors. For participants who are of childbearing potential and have had their first menses, the blood analysis will also include pregnancy testing. Laboratory testing will be performed at baseline, at three and six months while taking genistein and three months after the washout period. Urine samples will also confirm that genistein has been taken appropriately throughout the study.
The study expects that genistein will be well-tolerated by children, reduce BMI z-scores by 0.2 (0.5), and improve cardiometabolic risk factors such as blood pressure, lipid profiles, and inflammation. A sample size of 60 participants has been calculated to achieve statistically significant results, which will inform more extensive studies on genistein's potential for managing pediatric obesity.

开始日期2025-08-01

申办/合作机构

Western University

[+1]

CTRI/2025/03/083415

/ Not yet recruiting临床2期IIT

Effect of Genistein on Fecal Microbial Diversity, Modified Mayo Score, and Biomarkers in Patients with Ulcerative Colitis: A Placebo-Controlled Study. - NIL

开始日期2025-05-21

申办/合作机构-

NCT06741345

/ Recruiting临床1期

A Phase 1 Multiple Ascending Dose and Food Effect Trial of BIO 300 Oral Suspension in Healthy Volunteers

This is a two-part study of BIO 300 Oral Suspension in healthy male and female volunteers. The first part is a multiple ascending dose (MAD) study to test the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the drug when given as daily doses over 14 days. The study will enroll three cohorts each receiving a different daily dose: 2000 mg, 3000 mg, or 4000 mg. A fourth group may be added depending on results on the first three cohorts. Each cohort will include 10 participants (5 men, 5 women), with at least 8 completing all study steps. Participants will follow a special diet low in soy-based foods and will fast before certain doses. Blood samples and health checks will be done throughout the study to assess safety, drug is absorption and distribution in the body (PK), and its effects (PD). Safety will be reviewed after each group finishes to decide if the next dose level is safe to proceed.
The second part of the study is a food effect study to examine how food effects the PK of a single dose of BIO 300 Oral Suspension. This study will enroll 16 participants (8 men, 8 women) and will be split into two groups: one group will take the drug after fasting for 10 hours and the other will take the drug after eating a high-fat meal. After a 7-day break, participants will switch conditions (the previously fasted group will take the drug with food, and the previously fed group will take the drug after fasting). Blood samples and health checks will measure how food influences drug absorption (PK) and safety. Both the MAD study and food effect study aim to ensure the drug is safe and provide data on how it behaves in the body under different conditions.

开始日期2024-12-23

申办/合作机构

Humanetics Corp.

100 项与 Genistein 相关的临床结果

登录后查看更多信息

100 项与 Genistein 相关的转化医学

登录后查看更多信息

100 项与 Genistein 相关的专利（医药）

登录后查看更多信息

22,910

项与 Genistein 相关的文献（医药）

2025-12-31·Epigenetics

An overview of potential of natural compounds to regulate epigenetic modifications in colorectal cancer: a recent update

Review

作者: Duttaroy, Asim K. ; Philip, Neha ; Pathak, Surajit ; Siripragada, Sravani ; Roy, Susmita ; Banerjee, Antara ; Deka, Dikshita ; Ayyadurai, Pavithra ; Kondaveeti, Suresh Babu

Colorectal cancer (CRC) remains an alarming global health concern despite advancements in treatment modalities over recent decades. Among the various factors contributing to CRC, this review emphasizes the critical role of epigenetic mechanisms in its pathogenesis and progression. This review also describes the potential role of natural compounds in altering the epigenetic landscape, focused mainly on DNA methylation, histone modification, and non-coding RNAs. Publications from the previous five years were searched and retrieved using well-known search engines and databases like PubMed, Google Scholar, and ScienceDirect. Keywords like CRC/colorectal cancer, CAC/Colitis associated CRC, inflammasomes, epigenetic modulation, genistein, curcumin, quercetin, resveratrol, anthocyanins, sulforaphane, and epigallocatechin-3-gallate were used in various combinations during the search. These natural compounds predominantly affect pathways such as Wnt/β-catenin, NF-κB, and PI3K/AKT to suppress CRC cell proliferation and oxidative stress and enhance anti-inflammation and apoptosis. However, their clinical use is restricted due to their low bioavailability. However, multiple methods exist to overcome challenges like this, including but not limited to structural modifications, nanoparticle encapsulations, bio-enhancers, and novel advanced delivery systems. These methods improve their potential as supportive therapies that target CRC progression epigenetically with fewer side effects. Current research focuses on enhancing epigenetic targeting to control CRC progression while minimizing side effects, emphasizing improved specificity, bioavailability, and efficacy as standalone or synergistic therapies.

2025-12-31·Journal of the International Society of Sports Nutrition

Survey of nutritional intake status in college baseball players

Article

作者: Aoyama, Yuka ; Tanaka, Mamoru ; Seguchi, Manato ; Iio, Yoko ; Kozai, Hana ; Mori, Yukihiro ; Ito, Morihiro

BACKGROUND:

Diet is closely related to exercise performance. To improve athletes' performance and manage their condition, it is important to get sufficient energy and various nutrients. Thus, it is necessary that athletes understand their nutritional intake status to improve performance and maintain health. This study aimed to explore the nutritional intake status of college baseball players using the Food Frequency Questionnaire (FFQ). Furthermore, the characteristics of their nutritional intake status with respect to athletic performance were evaluated. The result of this studyprovide an opportunity for many under-developed college athletes with irregular lifestyles to recognize and improve their nutritional problems.

METHODS:

In October 2022, a questionnaire survey of 116 male members of a college baseball club was conducted. Of whom, 100 (94.3%) members responded to the survey and 92 (92.0%) provided valid responses. The survey items included basic characteristics such as college grade and type of living arrangement, and information on living conditions, e.g. whether the participant ate breakfast. Nutritional intake was evaluated using the FFQ. Players were divided into the first (regular players in official games), second (bench players in official games), third (players who may join the second or higher team in the future), and fourth teams (players who do not belong to the first to third teams); these categories were used as a marker of performance level. The Kruskal-Wallis test was used to analyze the association between the performance levels of baseball players and the intake of each nutrient and food group obtained by the FFQ. For items that showed a significant association, inter-group comparison was performed using the Dunn-Bonferroni method.

RESULTS:

Carbohydrate intake was greater in the second team compared with the third and fourth teams; saturated and monounsaturated fatty acid intake was higher in the third team compared with the fourth team. Calcium, zinc, copper, manganese, insoluble dietary fiber, iodine, and molybdenum intake was higher in the second team compared with the fourth team. Intake of grains, sugar, dairy, and total energy was significantly higher in the second team compared with the fourth team. However, the protein intake ratio was significantly lower in the second team compared with the fourth team. Overall, energy deficiency and associated deficiencies in protein, fat, and carbohydrate were observed, in addition to dietary fiber and calcium deficiencies. The intake of several food groups appeared inadequate, such as potatoes, beans, vegetables, fruits, eggs, milk, and fats.

CONCLUSIONS:

The study showed deficiencies in the amount of energy and nutrients such as protein, fat, and carbohydrate in college baseball players. Differences in the intake of carbohydrate, calcium, and insoluble dietary fiber among different performance levels were observed, with significantly higher intake of carbohydrate, calcium, and insoluble dietary fiber in the second team. Implementing organized and strategic remedial measures and athletes' identification of nutritional problems are vital to overcome nutritional and energy deficiencies. This study provides useful information for the development of strategies to support nutritional intake in college baseball players.

2025-12-31·Autophagy reports

Untangling Traffic Jams: RAB11FIP4 Orchestrates Cellular Recovery in Cystinosis

Article

作者: Johnson, Jennifer L. ; Catz, Sergio D. ; Ait Kbaich, Mouad

RAB11FIP4 (RAB11 family interacting protein 4), a RAB11A (Ras-related protein Rab-11) effector protein downregulated in cystinosis, plays a crucial role in cellular trafficking. Reconstitution of RAB11FIP4 in cystinotic cells restores multiple cellular functions, including lysosomal trafficking, autophagy, and the endoplasmic reticulum stress response. These findings identify RAB11FIP4 as both a key player in cystinosis pathogenesis and a promising therapeutic target. The purpose of this punctum is to highlight how restoring RAB11FIP4 expression rescues cellular homeostasis in cystinosis through the regulation of trafficking pathways.

项与 Genistein 相关的新闻（医药）

2025-03-17

·GlobeNewswire-Health Care

Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome

Humanetics’ Novel Radioprotective Agent Being Developed with Funding from Department of Defense as Radiation Medical Countermeasure (MCM) Lifecore to Carry Out Tech Transfer and Analytical Method Activities, including Filling of Pilot Batch CHASKA, Minn. and MINNEAPOLIS, March 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and Humanetics Corporation (“Humanetics”), an advanced clinical-stage pharmaceutical company, today announced that Humanetics has selected Lifecore to provide a range of CDMO services to support the continued development of BIO 300 for the prevention of acute radiation syndrome. Under the terms of the agreement, Lifecore will conduct technology transfer of the existing fill and finish process for BIO 300, including formulation development, gap assessment, and filling of a pilot batch. Lifecore will also undertake analytical method work including feasibility assessments designed to estimate future development work for the product candidate. “This relationship represents another important example of the momentum that we are generating at Lifecore as we execute against our strategic growth plan. Humanetics’ BIO 300 is the exact type of promising, cutting-edge biopharmaceutical product that we strive to support, and we are gratified to have been selected by the company to provide these services,” said Paul Josephs, chief executive officer of Lifecore. “Additionally, this collaboration between two Minnesota-based life science companies helps shine a spotlight on the impressive medical innovation that is coming out of our state, and we are thrilled to be able to support the important work being advanced by Humanetics.” “We are excited about working with Lifecore in our own backyard, showcasing the exceptional talent and innovation Minnesota has to offer,” said Ronald Zenk, chief executive officer of Humanetics. “Results of this collaboration will help provide critical protection against exposure to radiation for warfighters, First Responders and civilian populations worldwide.” In addition to the acute radiation syndrome program, BIO 300 is currently in late-stage clinical development for the mitigation of impaired pulmonary function in COVID-19 patients recently discharged from the hospital. Humanetics recently announced promising data from a Phase 2 clinical trial of BIO 300. The compound is also in development for oncology applications to protect cancer patients from unintentional side effects caused by radiation therapy. AcknowledgementThe U.S. Army Medical Research Acquisition Activity, 808 Schreider Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office. This work was supported by The Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, in the amount of $5,132,520 through the Peer Reviewed Medical Research Program under Award Number W81XWH-22-1-0516. Opinions, interpretations, conclusions, and recommendations are those of the author(s) and are not necessarily endorsed by The Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense. About Lifecore Biomedical Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com. About Humanetics CorporationHumanetics is an advanced clinical-stage pharmaceutical company engaged in the accelerated discovery, development, and commercialization of proprietary drugs in markets with urgent and unmet needs, with a focus on medical countermeasures, radiation modulators for oncology and inflammatory lung diseases. For more information, visit www.humaneticscorp.com. Important Cautions Regarding Forward-Looking Statements This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements. In addition, all statements regarding our anticipated future operating and financial expectations, customer opportunities and relationships are forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors among others, as the company’s ability to successfully enact its business strategies, including with respect to installation, capacity generation and its ability to attract demand for its services, and its ability expand its relationship with its existing customers or attract new customers; the impact of inflation on Lifecore’s business and financial condition; changes in business conditions and general economic conditions both domestically and globally, including rising interest rates and fluctuation in foreign currency exchange rates; Lifecore’s ability to access sufficient capital to fund its business strategies; and other risk factors set forth from time to time in Lifecore’s SEC filings, including, but not limited to, the Annual Report on Form 10-K for the year ended May 26, 2024 (the “2024 10-K”). For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to our filings with the Securities and Exchange Commission, including the risk factors contained in the 2024 10-K. Forward-looking statements represent management’s current expectations as of the date hereof and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances. Lifecore Biomedical, Inc. Contact Information: Vida Strategic PartnersStephanie Diaz (Investors)415-675-7401sdiaz@vidasp.com Tim Brons (Media)415-675-7402tbrons@vidasp.com Ryan D. Lake (CFO)Lifecore Biomedical952-368-6244ryan.lake@lifecore.com

临床2期放射疗法引进/卖出

2025-02-25

·Business Wire

Humanetics Corporation Chief Medical Officer Is Featured Guest at U.S. Industry, National Security, and Healthcare Forum

MINNEAPOLIS--(BUSINESS WIRE)--Humanetics Corporation, an advanced clinical-stage specialty pharmaceutical company developing radioprotectant drugs for warfighters and patients with cancer and inflammatory lung diseases, today announced that its Chief Medical Officer, Rear Admiral Colin G. Chinn, MD, MHS, FACP (Ret.), will be a featured guest at a private industry, national security, and healthcare forum on February 27, 2025 in Naples, FL, entitled “Advancing America’s Future in Critical Industries.” Dr. Chinn will address “Breakthroughs in Radiation Protection for Military & Healthcare.” About BIO 300 Humanetics is pioneering the development of BIO 300, a groundbreaking radioprotectant drug. This innovative medical countermeasure, which can be used in military and medical contexts, is designed to provide whole-body protection against radiation damage, setting it apart from other drug candidates. BIO 300 has received considerable attention, funding, and research from the Department of Defense (DoD) for its potential to mitigate the harmful effects of radiation among warfighters and civilians in the event of a nuclear attack or radiological incident. The need for such a medical countermeasure has escalated significantly given current world events. Humanetics is currently working under a contract with DoD to approve BIO 300 for use under Emergency Use Authorization to provide prophylactic protection to warfighters across the globe. BIO 300 is also indicated for use as a new class of drug to improve outcomes in cancer patients who received first-line radiotherapy with or without concurrent chemotherapy. These patients suffer myriad side effects that can reduce the efficacy of treatment or result in serious toxicities. BIO 300 selectively protects normal tissue but not cancer tumors, thereby improving therapeutic outcomes. BIO 300 is currently undergoing Phase 2 clinical trials, marking a significant milestone in its development. The trials aim to evaluate its effectiveness in preventing normal tissue injury from cancer radiotherapy and reducing lung damage in COVID-19 long-haul patients (results recently announced). Administered as an oral liquid, BIO 300 has shown potential to minimize radiation damage in normal tissue without compromising the effectiveness of radiation therapy against the tumor. Positive results from the Phase 1b/2a clinical trial in non-small cell lung cancer patients undergoing chemoradiotherapy further bolster BIO 300 prospects, highlighting its safety and potential for positive clinical outcomes. About Humanetics Corporation Humanetics is an advanced clinical-stage pharmaceutical company engaged in the accelerated discovery, development, and commercialization of proprietary drugs in markets with urgent and unmet needs, with a focus on medical countermeasures, radiation modulators for oncology, and inflammatory lung diseases. For more information, visit www.humaneticscorp.com.

放射疗法临床2期

2025-01-22

·Business Wire

Humanetics Corporation Announces Positive Phase 2 Clinical Trial Results in COVID-19 Study Aimed at Improving Pulmonary Function

MINNEAPOLIS--( BUSINESS WIRE )--Humanetics Corporation (Humanetics) announced today the results of its Phase 2 clinical trial of BIO 300 Oral Suspension (BIO 300) for the mitigation of impaired pulmonary function in COVID-19 patients recently discharged from the hospital. BIO 300 is an oral drug that patients self-administer daily for 12 weeks following hospital discharge. The study compared the lung function, exercise capacity, and quality of life in COVID-19 survivors who received BIO 300 against a placebo group. The trial enrolled 38 participants across multiple U.S. sites ( NCT04482595 ). Rany Condos, MD, a clinical Professor in the Department of Medicine at NYU Grossman School of Medicine and Director of its Post-COVID Program, served as the lead investigator. Patients previously hospitalized with COVID-19 complications and discharged with residual lung complications (e.g., long COVID) were eligible if enrolled within two years of discharge. Multiple pulmonary function assessments and a patient-reported quality of life questionnaire were used to evaluate BIO 300’s efficacy. Although the study fell short of its planned enrollment of 50 participants, the 20 BIO 300-treated participants within the enrolled cohort of 38 exhibited improved lung function and participant-reported quality of life compared to placebo-treated participants. Key Trial Findings: Improvement in Pulmonary Function: Participants who received BIO 300 demonstrated a statistically significant improvement in pulmonary function at 12 weeks, which was maintained at 12 months, as measured by forced expiratory volume in one second (FEV1). Additionally, clear statistical trends for improved pulmonary function were observed in BIO 300-treated participants at 12 weeks, 6 months, and 12 months, as measured by the diffusing capacity of the lung for carbon monoxide (DLCO) and forced vital capacity (FVC). Quality of life: Participants treated with BIO 300 showed a clear trend toward an improved quality of life as measured by the St. George’s Respiratory Questionnaire at 6 months, which was maintained at 12 months. Safety Profile: BIO 300 treatment was well-tolerated, with adverse events consistent with those expected in this patient population. No new safety concerns were identified during the trial. "We are highly encouraged by the results of this clinical trial, particularly the promising trends in pulmonary function improvement among COVID-19 participants treated with BIO 300," said Michael Kaytor, PhD, Vice President of Research and Development at Humanetics. "We are continuing to evaluate the data to refine our understanding of BIO 300’s efficacy in COVID-19 and its potential applications for improving patient outcomes." BIO 300 is also in development as a medical countermeasure for use by the United States Department of Defense and for oncology applications to protect patients from side effects caused by radiation. "As BIO 300 has been shown to mitigate inflammation of the lungs and pulmonary fibrosis caused by radiation, we believe that the same effect can be shown in COVID-19 patients,” said Ronald J. Zenk, Chief Executive Officer at Humanetics. “We are optimistic that this treatment could be a valuable addition to the ongoing efforts to combat long COVID and other conditions with lung inflammation and are committed to evaluating its impact in future studies.” This project was funded by the National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health, Department of Health and Human Services, under Contract HHSN272201800011C. About Humanetics Corporation Humanetics is an advanced clinical-stage pharmaceutical company engaged in the accelerated discovery, development, and commercialization of proprietary drugs in markets with urgent and unmet needs, with a focus on medical countermeasures, radiation modulators for oncology and inflammatory lung diseases. For more information, visit www.humaneticscorp.com .

临床2期临床结果放射疗法

100 项与 Genistein 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11680	Genistein	-	DB01645

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
儿童肥胖	临床2期	-	Western University	2025-08-01
射血分数降低的心力衰竭	临床2期	加拿大	Greenstone Biosciences, Inc.	2024-09-27
转甲状腺素蛋白淀粉样变性心肌病	临床2期	加拿大	Greenstone Biosciences, Inc.	2024-09-27
心脏衰竭	临床2期	斯洛文尼亚	Greenstone Biosciences, Inc.	2024-07-01
肺损伤	临床2期	美国	Humanetics Corp.	2022-04-27
新冠肺炎后遗症	临床2期	美国	Humanetics Corp.	2020-11-11
肺纤维化	临床2期	美国	Humanetics Corp.	2020-11-11
非肌层浸润性膀胱肿瘤	临床2期	美国	National Institutes of Health	2017-05-19
非小细胞肺癌 II期	临床2期	美国	Humanetics Corp.	2015-11-01
晚期恶性实体瘤	临床2期	加拿大	Uman Pharma, Inc.	2012-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01489813 (CTgov)	临床2期	非肌层浸润性膀胱肿瘤	36	sugar pill (Sugar Pill)	繭餘齋夢鹹齋顧觸糧餘(艱窪鹹觸鑰廠積製獵觸) = 網襯襯網鬱鹽窪積鏇衊夢觸獵範廠鑰憲蓋簾廠 (範憲鏇願糧憲衊糧鬱夢, 鏇鑰鹹壓憲夢鹽蓋網壓 ~ 襯選膚築齋憲餘構顧齋) 更多	-	2024-07-25
				Genistein (Genistein Supplement)	繭餘齋夢鹹齋顧觸糧餘(艱窪鹹觸鑰廠積製獵觸) = 獵願淵簾憲遞艱壓繭顧夢觸獵範廠鑰憲蓋簾廠 (範憲鏇願糧憲衊糧鬱夢, 顧鹽選醖觸簾襯蓋範鏇 ~ 膚蓋鹽鑰鹽顧鬱簾範觸) 更多
EULAR2024	N/A	大动脉炎	-	Genistein	鬱網鹹觸顧窪窪獵積醖(繭鏇繭觸鬱範鹽鏇憲鬱) = 簾選積鹽夢構鏇廠膚窪觸齋簾壓淵淵壓觸鬱淵 (齋獵獵齋繭獵簾衊觸衊 )	积极	2024-06-05
NCT02624388 (UVA-Gen001, CTgov)	临床2期	霍奇金淋巴瘤 \| 肾母细胞瘤 \| 儿童恶性实体瘤 ... 更多	4	Placebo+Genistein (Arm A: Genistein Followed by Placebo)	願觸艱鏇衊鹽廠顧膚淵(積遞鏇觸淵範淵獵壓製) = 觸顧醖觸範製鬱夢鏇鏇築醖衊選廠積衊齋簾遞 (積鹹醖鏇製蓋構鬱夢膚, 1.26) 更多	-	2024-05-06
				Placebo+Genistein (Arm B: Placebo Followed by Genistein)	願觸艱鏇衊鹽廠顧膚淵(積遞鏇觸淵範淵獵壓製) = 艱鬱選淵鹹鹹網衊觸餘築醖衊選廠積衊齋簾遞 (積鹹醖鏇製蓋構鬱夢膚, 2.08) 更多
NCT04650555 (CTgov)	临床1期	急性放射综合征	34	BIO 300 Oral Powder (Single Ascending Dose Cohort 1)	鑰廠鏇糧醖鹹糧壓醖鏇(蓋築願積艱積齋艱窪顧) = 構憲鑰鬱獵憲網積齋壓夢獵鹽夢鹽選製憲顧鏇 (網鬱製選選獵窪願壓積, 9.3) 更多	-	2024-05-03
				BIO 300 Oral Powder (Single Ascending Dose Cohort 2)	壓選網憲艱襯遞齋鹽獵 = 糧窪積築鏇顧壓襯鹹蓋網餘鹹艱願衊鏇鏇醖願 (遞選顧範鬱淵憲齋襯遞, 積鏇窪築襯範鏇壓衊齋 ~ 糧願遞鹹構構積衊齋鹽) 更多
NCT02567799 (NSCLC, CTgov)	临床1/2期	非小细胞肺癌 II期 \| 非小细胞肺癌	21	BIO (BIO 300 Oral Suspension (500 mg/Day))	淵醖構鑰鑰鑰餘艱築範 = 築鏇蓋蓋廠醖觸鬱壓鑰範膚鹹窪艱鑰窪窪築蓋 (積觸範壓築壓範夢範齋, 築淵鏇膚選鏇構壓衊衊 ~ 餘窪選餘齋憲窪築壓簾) 更多	-	2023-12-20
				BIO (BIO 300 Oral Suspension (1000 mg/Day))	淵醖構鑰鑰鑰餘艱築範 = 積醖簾齋構廠觸遞餘壓範膚鹹窪艱鑰窪窪築蓋 (積觸範壓築壓範夢範齋, 醖範鹽選醖網獵衊鏇艱 ~ 艱鑰願鹹製觸膚憲範衊) 更多
NCT02567799 (Biospace) 人工标引	临床1/2期	非小细胞肺癌	21	BIO 300	夢觸壓醖製鹹築願簾願(繭網糧選夢蓋觸醖鏇襯) = 膚窪窪繭鏇膚構製醖獵簾餘糧願築積遞鹽繭鏇 (簾夢襯襯鬱選獵糧鏇選 ) 更多	积极	2023-09-19
NCT02766478 (GeniPro, CTgov)	临床2期	前列腺癌 \| 代谢性疾病	10	Genistein (Genistein)	膚鏇獵鹹壓蓋構艱夢鏇(鹹衊窪衊鑰夢夢鹽衊醖) = 築襯積網鬱夢簾構壓網顧齋廠餘糧積憲製糧淵 (積願壓觸繭夢蓋顧壓鏇, 鹹獵鏇齋襯顧鑰簾遞艱 ~ 齋餘襯築餘窪鹽網繭製) 更多	-	2022-09-27
				Placebo (Placebo)	膚鏇獵鹹壓蓋構艱夢鏇(鹹衊窪衊鑰夢夢鹽衊醖) = 積選鏇獵壓鑰鬱觸顧願顧齋廠餘糧積憲製糧淵 (積願壓觸繭夢蓋顧壓鏇, 餘範鑰艱鏇觸遞憲夢簾 ~ 壓蓋範艱廠衊願鏇衊網) 更多
NCT04650555 (BusinessWire) 人工标引	临床1期	-	34	BIO 300	餘鏇蓋選觸築網積膚餘(壓鬱餘範觸鬱構積艱齋) = increase survival in persons exposed to lethal levels of radiation 窪製糧蓋鏇鏇獵艱觸蓋 (築鑰獵鏇簾窪鏇獵構鏇 )	积极	2021-09-22
NCT01985763 (Pubmed \| Cancer Chemother Pharmacol) 人工标引	临床1/2期	转移性结直肠癌	13	FOLFOX+Bevacizumab+Genistein	壓繭獵觸齋齋築蓋廠願(簾鬱壓衊鹹衊網醖鬱構) = 1patirent (grade 3 hypertension) 壓範衊願構築鬱淵網積 (積顧網積範淵範繭鬱夢 ) 更多	积极	2019-09-01
NCT00287690 (CTgov)	临床2/3期	冠心病	71	Genistein (Genistein)	製觸窪膚繭艱壓鏇選鏇(選願鏇鏇鬱遞遞壓鏇衊) = 窪醖蓋餘觸淵築鬱鏇壓鑰齋膚襯醖壓獵膚範蓋 (願顧淵壓衊醖衊鬱範繭, 0.4) 更多	-	2019-08-05
				Placebo (Placebo)	製觸窪膚繭艱壓鏇選鏇(選願鏇鏇鬱遞遞壓鏇衊) = 餘網鹽鑰憲網選廠顧獵鑰齋膚襯醖壓獵膚範蓋 (願顧淵壓衊醖衊鬱範繭, 0.4) 更多